FDC jumps 6% after launching 2 variants of Covid-19 drug Favipiravir

The price per tablet is Rs 55 for both the variants

Shares of drug firm FDC Ltd on Wednesday rose as much as 6.12 per cent to Rs 336.95 on the BSE after the company launched two variants of the Covid-19 drug Favipiravir under the brand names PiFLU and Favenza.

The Drug Controller General of India (DCGI) had earlier approved the use of Favipiravir, an off-patent, oral antiviral drug that has been shown to quicken clinical recovery in Covid-19 patients with mild to moderate symptoms, FDC said in a statement to the exchanges yesterday.

"Early diagnosis and treatment will help in arresting the deteriorating condition of patients, and we will be working with